ASX:ILAPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals
ISLAND PHARMACEUTICALS ORD
$0.425
+$0.075 (+21.43%)
Day Range
$0.355 - $0.470
52 Week Range
$0.130 - $0.630
Volume
2.31M
Avg Volume (10D)
192.53K
Market Cap
$125.76M
Price Chart
Market Statistics
Open$0.355
Previous Close$0.350
Day High$0.470
Day Low$0.355
52 Week High$0.630
52 Week Low$0.130
Valuation
Market Cap125.76M
Shares Outstanding295.92M
Price to Book13.16
Trading Activity
Volume2.31M
Value Traded972.69K
Bid$0.425 × 1,533
Ask$0.435 × 15,286
Performance
1 Day6.06%
5 Day-0.71%
13 Week-9.09%
52 Week94.44%
YTD-18.60%
Technical Indicators
RSI (14)66.22
50-Day SMA$0.380
200-Day SMA$0.379
Latest News
Biotechnology
Island Pharma Expands Antiviral Pipeline with Burnet Institute Collaboration and NHMRC Funding
Island Pharma expands antiviral pipeline with Burnet Institute; NHMRC grant of over $780k to back ISLA-101, accelerating Galidesivir MVD program.
1 min read
Biotechnology
Island Pharma Partners with USAMRIID and Geneva Foundation for Galidesivir under FDA Animal Rule
Island Pharma signs a 3-year CRADA with USAMRIID and Geneva Foundation to fast-track Galidesivir for Marburg under FDA Animal Rule, eyeing NDA.
1 min read
Biotechnology
Island Pharmaceuticals Raises $9m to Fund Clinical Development as FDA Approves Galidesivir Pathway
Island Pharmaceuticals (ASX: ILA) secures FDA Animal Rule path for galidesivir and $9m funding to fast-track two-stage trials and US govt procurement potential.
1 min read
Biotechnology
Island Pharmaceuticals and Texas Biomed to Conduct Non-Human Primate Studies Using Antiviral Drug Galidesivir
Island Pharmaceuticals (ASX: ILA) has secured a master service agreement with Texas Biomedical Research Institute to support the development of lead antiviral molecule galidesivir.
1 min read